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ABSTRACT
Background: Omalizumab, a monoclonal anti-IgE antibody, is currently indicated for the treatment of
moderate-to-severe allergic asthma. To measure active IgE levels in sera from patients treated with omalizu-
mab, the IgE subfraction in complex with omalizumab should be eliminated from total IgE, and free IgE levels
can then be determined. With the aim of therapeutic monitoring for anti-IgE therapy, we developed a new
ELISA for free IgE.
Methods: We used recombinant human soluble FcεRIα as a capture antigen and a biotinylated polyclonal
anti-IgE antibody for detection. Using the newly developed ELISA, we measured the serum free IgE levels
weekly in four asthmatic patients after their first omalizumab injection. We also measured the serum free IgE
levels in 54 patients treated with omalizumab for over 4 weeks.
Results: This assay was technically robust, the mean recovery rate in serum was 93.16% ± 5.34%. For all pa-
tients, omalizumab treatment significantly reduced serum free IgE levels prior to the second omalizumab injec-
tion. To maintain the benefit of omalizumab, serum free IgE concentrations should be <50 ngml. However, in
14 of 54 patients treated with omalizumab for over 4 weeks, serum free IgE concentrations measured by our
ELISA were >50 ngml.
Conclusions: Our data suggest that the measurement of free IgE levels using our newly developed ELISA
would be useful for monitoring serum free IgE levels during omalizumab therapy.
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INTRODUCTION
Atopic asthma is a chronic airway disease involving
the inflammation of the airway resulting from allergic
reactions triggered by the binding of an inhaled anti-
gen to antigen-specific IgE. The inhaled antigen
binds to IgE, and this antigen-bound IgE cross-links
to high-affinity IgE receptors on the surface of mast
cells and basophils, thereby inducing the release of
mediators that cause airway constriction and inflam-
mation. Allergen immunotherapy, in which a specific
antigen is administered over a long period of time, is
one of the IgE-targeting approaches for treating bron-
chial asthma.1 However, this therapy is ineffective for
certain patients such as those who are sensitized to
multiple antigens.
Omalizumab, a humanized anti-IgE antibody, is
currently the most effective therapy among clinically
available IgE-targeting therapies.2,3 Administered
omalizumab is known to bind to the Fc region of se-
rum IgE, inhibiting the binding of IgE to FcεRIα on
the surface of mast cells and basophils. This thereby
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prevents the degranulation of these cells, suppress-
ing the release of inflammatory mediators.4 More-
over, preventing IgE from binding to high-affinity IgE
receptors for a certain period is considered to sup-
press their expression on the surface of mast cells in
tissues as well as circulating basophils.5 Conse-
quently, the numbers of eosinophils, T lymphocytes,
B lymphocytes, and Th2 cytokine-positive cells de-
crease in the sputum and airway mucosal tissues;5 IL-
5IL-13 levels reduce in blood and tissues, and aller-
gic reactions are suppressed.6,7
In Japan, omalizumab is considered as a therapeu-
tic option for Step V of the Global Initiative for
Asthma (GINA) guideline, which is the treatment
step for patients with the most severe and persistent
symptoms that cannot be controlled by combination
asthma therapy comprising high-dose inhaled ster-
oids and long-acting β2-agonists.8,9 Among severe
asthmatic patients who underwent omalizumab treat-
ment, 60.1% have been reported to show improve-
ments in their symptom scores.4,9 Furthermore,
omalizumab treatment has few side effects. There-
fore, it is considered to be safe and effective for treat-
ing severe asthmatic patients.10,11
However, responders and nonresponders to omali-
zumab therapy have been observed, even among
atopic asthmatic patients.12,13 Although no known in-
dicator for predicting the therapeutic response is
available, even for asthmatic patients having IgE anti-
bodies to inhaled antigens, responders can be identi-
fied comprehensively based on, for example, asth-
matic attack frequency, QOL, and respiratory func-
tion at 16 weeks after administration of the agent.
Subsequently, judgments are made as to whether ad-
ditional administrations are warranted. The recently
reported EXTRA study14 revealed that after 46 weeks
of omalizumab treatment, groups with higher blood
eosinophil, serum periostin, and exhaled nitric oxide
(FeNO) levels responded better to this therapy.
Besides the respondernonresponder issue, dos-
age selection is another factor that influences the
therapeutic effect of omalizumab. The dose of omali-
zumab is calculated based on body weight and total
blood IgE levels measured before initiating the ad-
ministration.15 However, blood IgE levels fluctuate
throughout the year,16 which precludes the assur-
ance of the therapeutically adequate dosage based on
the pretreatment IgE levels for the reasons discussed
below.
When IgE production increases after the therapy
has been initiated, the required dose may be underes-
timated, and some patients can be misidentified as
nonresponders simply because a therapeutically ade-
quate dose was not given. In contrast, overdosing can
occur when a patient’s IgE production decreases dur-
ing the treatment. As described above, omalizumab is
the only effective molecular-targeted therapeutic
agent available for severe asthmatic patients, and
proper monitoring of IgE levels as the therapeutic tar-
get is important to avoid underdosing.
Current methods clinically available for measuring
serum IgE levels do not distinguish IgE antibodies in
complex with omalizunmab from free antibodies. To
measure active IgE levels in sera from patients
treated with omalizumab, the IgE subfraction in com-
plex with omalizumab should be eliminated from total
IgE, and free IgE levels can be then determined. Till
date, several methods to measure free IgE levels in
sera from patients undergoing omalizumab treatment
have been reported.17,18 In many previous clinical tri-
als, serum free IgE levels have been measured using
a combination of rshFcεRIα and an anti-IgE antibody.
However, this method poses some problems, as fol-
lows: 1) information on the accuracy and precision of
the measurement system is not publicly available,
and 2) the measurement cost is high owing to out-
sourcing.
The recombinant rshFcεRIα protein preparations
used in previous studies17,18 were mostly expressed
in Escherichia coli or insect cells using baculovirus
vectors. Although their amino acid sequences have
been shown to be identical to those of the human pro-
tein, their sugar chain structures could have been dif-
ferent from the human counterparts. A difference in
the sugar chain structure could affect the binding af-
finity of IgE and its receptor FcεRIα, thereby affect-
ing the measurement results.
In this study, we aimed to develop an original assay
system for determining free IgE levels in sera using
the recombinant high-affinity IgE receptor FcεRIα
with the human form of sugar chains (rshFcεRIα),
which was expressed in Chinese hamster ovary
(CHO) cells, as the capture antigen. Our ultimate aim
was to establish a method to quantify free IgE levels
in sera from patients being treated with omalizumab.
METHODS
REAGENTS AND EQUIPMENT
Human IgE (Thermo Fisher Scientific, New York,
USA) was used as a reference standard. A mouse
anti-human IgE horseradish peroxidase (HRP)-
conjugated antibody (Cat#: 61I58A) was obtained
from Fitzgerald Industries International (Massachu-
setts, CA, USA). An anti-human Fc-epsilon Receptor I
alpha monoclonal antibody clone AER-37 (CRA1; Cat
#: 16-5899-82) was obtained from eBioscience (San
Diego, CA, USA). Bovine serum albumin (BSA; Cat#:
A-3059) and Tween-20 (Cat#: 170-6531) were from
Sigma-Aldrich (St. Louis, MO, USA). A Multiskan GO
microplate spectrophotometer was obtained from
Thermo Fisher Scientific. The commercial products
of omalizumab was obtained from Novartis Pharma-
ceuticals (Tokyo, Japan).
PREPARATION OF rsFcεRIα
rsFcεRIα was prepared in our laboratory as previ-
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Fig.　1　Purifi cation of recombinant hsFcεRIαa as a stan-
dard protein for quantifying human IgE by ELISA. Standard 
samples were analyzed for purity using Coomassie Blue 
staining, which revealed the major band (50 kDa) represent-
ing rsFcεRIα.
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ously described.19 In brief, the culture supernatants
from CHO cells that secreted rsFcεRIα were col-
lected. This supernatant was concentrated using a
Centricon-Plus 70 concentrator (Millipore, Bedford,
MA, USA). The rsFcεRIα protein was purified from
the supernatant using an affinity column (HiTrap
NHS-activated HP column; GE Healthcare Bio-
sciences, Little Chalfont, UK) that was coupled with 5
mg of an anti-human FcεRIα mAb (CRA1). Standard
samples were analyzed for purity using Coomassie
Blue staining (Fig. 1), which revealed the major band
(approximately 50 kDa) representing rsFcεRIα.
IgE ELISA PROCEDURE
Microtiter plates were coated with rshFcεRI (from
0.05 to 0.15 μgwell) and incubated overnight at 4℃.
Subsequently, excess rshFcεRI was washed away.
For all washing steps, microplates were rinsed three
to five times with the washing buffer (PBS0.05%
Tween-20, 300 μlwell). Wells were blocked with
PBS1% BSA (200 μlwell) for 1 h at 25℃. For a stan-
dard curve, eight serial dilutions of human IgE rang-
ing from 4.69 ngml to 600 ngml were prepared in
the sample diluent (PBS0.05% Tween-20 and 1%
BSA). Plates were washed and incubated with stan-
dards or samples in duplicate (100 μlwell). After 2 h
at 25℃, plates were washed, and wells were filled
with the secondary detection antibody (mouse anti-
human IgE HRP-conjugated antibody, 11000 in
PBS1% BSA, 100 μlwell) for 1 h at room tempera-
ture. After washing, the TMB substrate solution was
added (100 μlwell). After 10 min., the HRP reaction
was stopped using 2 N H2SO4 (50 μlwell). Optical
density (OD) was then measured at 450 nm using a
96-well microplate reader. The goodness of fit (R2) of
the standard curve was assessed using a four-
parameter logistic regression algorithm calculated
with Skanit software (Thermo Fisher Scientific). Data
were analyzed using GraphPad Prism software
(GraphPad, San Diego, CA, USA).
SAMPLES FROM HEALTHY VOLUNTEERS AND
ASTHMATIC PATIENTS
To validate the standardized method for measure-
ment of IgE, we obtained serum samples from seven
healthy controls, 54 asthmatic patients treated with
omalizumab (age range: 19-86 years; median age: 54
years), and seven asthmatic patients not treated with
omalizumab. The patients were diagnosed according
to the GINA guidelines. Patient’s serum samples
were stored at -80℃ prior to analysis. Total IgE con-
centrations were determined using Total IgE Im-
munoCap (Thermo Fisher Scientific), with the results
of IgE concentration expressed as International Units
(kUl). IgE concentrations in kUl were converted to
ngml by multiplication with 2.4. All patients treated
with omalizumab had severe asthma according to the
GINA guidelines and showed positive reactions for
serum-specific IgE tests against inhaled allergens. Se-
rum samples were obtained weekly from five patients
after the first administration of omalizumab.
This study was approved by the Institutional Re-
view Board of Nihon University School of Medicine
and Juntendo University School of Medicine, and all
samples were collected after informed consent was
obtained from patients.
DILUTIONAL LINEARITY ASSESSMENT FOR IgE
ELISA
The specificity of the assay was evaluated by omitting
the detection antibody. Serum IgE concentrations
were determined by interpolation from the four-
parameter logistic regression algorithm of the stan-
dard curve with Skanit software. The dilution linearity
of the assay was assessed using diluted samples. Se-
rum samples obtained from 13 healthy controls were
diluted with the sample diluent in the range from 1 : 2
to 1 : 32. In addition, the serum samples from five
asthmatic patients were diluted with the sample dilu-
ent in the range from 1 : 10 to 1 : 20.
SPIKE-RECOVERY ASSAYS FOR IgE ELISA
We performed spike-recovery assays to test for ma-
trix interference.20 As a standard sample, we used a
mixture of pooled serum samples obtained from six
male and six female healthy controls with relatively
low IgE levels. The final IgE concentration in this
pooled serum was 193 ngml. The pooled serum was
diluted to 1 : 15 and spiked by adding IgE (final con-
centrations ranging from 4.69 ngml to 600 ngml) to
the standard solution. The recovery rate (%) was cal-
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culated by dividing the IgE concentration measured
using ELISA by the theoretical concentration of the
samples (IgE concentration in the pooled serum +
IgE concentration of unspiked IgE). The assay was
determined to be at an acceptable level when the re-
covery rates were between 80% and 120%.20-22
PRECISION OF IgE ELISA
The precision of the assay was evaluated by inter- and
intra-assay variability tests. A total of 75 ngml of IgE
was added to the serum samples obtained from seven
healthy controls and seven asthmatic patients. For
the intra-assay variability test, we analyzed five repli-
cates of individual samples on the same plate. Inter-
assay variability was assessed using replicates of a
sample on four different plates by two independent
operators. The assay was determined to be at an ac-
ceptable level when the mean recovery rate was
within 20% of the theoretical concentration and the
corresponding percentage of coefficient of variation
(CV%) was <20%.20-22
OMALIZUMAB AND IgE COMPLEX PREPARA-
TION
Human IgE was diluted with the sample diluent at
1200 ngml and then mixed with equal volumes of
the sample diluent or omalizumab ranging from 2.34
ngml to 600 ngml. These mixtures were incubated
for 30 min at room temperature to enable complex
formation prior to the analysis for free IgE level
measurements. The final IgE concentration in the ab-
sence of omalizumab (buffer control condition) was
600 ngml.
RESULTS
PREPARATION OF STANDARDS
The scheme of measurement of free IgE levels in se-
rum samples from patients who were treated with
omalizumab is shown in Figure 2A. An eight-point se-
rial dilution of human IgE in the range from 4.69 ng
ml to 600 ngml was used to generate the standard
curve (Fig. 2B). Curve-fitting analysis was performed
using the four-parameter logistic regression algo-
rithm with the measured OD and the absolute IgE
concentration. The average goodness of fit (R2) for
eight individual experiments was 0.999. To evaluate
the specificity of detecting IgE with ELISA using
rsFcεRIα and an anti-IgE antibody, the detection anti-
body was omitted and resulted in a loss of IgE-
derived signals for all concentrations (Fig. 2C).
DETERMINATION OF THE OPTIMAL DILUTION
FACTOR FOR SERUM SAMPLES
To determine the optimal dilution factor for serum
samples for quantification of IgE in serum, serum
samples obtained from six healthy controls with vari-
ous IgE concentrations were diluted at the indicated
dilution factors, and ELISA was performed. As shown
by the results in Figure 3A, the OD values were al-
most the same at the dilution factors between ×16 and
×32, but the OD values decreased at the dilution fac-
tors below ×8. We considered that the binding be-
tween IgE and rsFcεRIα was inhibited by serum fac-
tor(s) at the dilution factors between ×8 and ×15. As
shown in Figure 3B, we measured serum IgE levels
for samples diluted by the factors of ×10, ×15, and ×20
and checked the linearity of OD values. In serum
from healthy controls and serum from asthmatic pa-
tients, the OD values were almost the same at dilu-
tion factors between ×15 and ×20, but the OD values
decreased at dilution factors below ×10. From these
results, we determined that the optimal dilution factor
was ×15 for this assay to perform highly sensitive
measurement of IgE in serum without interference
from serum factors.
ACCURACY OF ELISA
To evaluate the accuracy of the assay, we used a
spike recovery assay. We measured eight different
spike concentrations in the pooled serum obtained
from 12 individual healthy controls (six males and six
females). As shown Table 1, the recovery rates were
between 80% and 120%, and the CV% values were
<20% when we measured spike concentrations rang-
ing from 9.38 ngml to 600 ngml. According to a
guideline on bioanalytical method validation for clini-
cal research by Food and Drug Administration
(FDA),23 we conclude that the working ranges for
this assay were as follows: lower limit of quantitation
(LLOQ) =9.38 ngml and upper limit of quantitation
(ULOQ) =600 ngml. These are corresponding to
140.7 ngml and 9000 ngml of serum IgE of concen-
tration respectively.
We next examined the recovery rates of the spikes
in each serum sample obtained from seven healthy
controls and seven asthmatic patients. The mean re-
covery rate was 111.3% ± 9.7%, which met our preset
acceptance level (Table 2). One sample obtained
from a healthy control had a recovery of >120%
(125%), suggesting a possible matrix interference in
this patient.
Table 3, 4 show the results of our intra-assay and
inter-assay variability tests. The mean recovery rate
was within 20% of the absolute concentration with a
corresponding CV% of <20% for all the three tested
concentrations. These results met the acceptance cri-
teria for immunoassay validation.20-22
MEASUREMENT OF FREE IgE IN PATIENTS
TREATED WITH OMALIZUMAB
To confirm the mutual exclusion of IgE bound with
omalizumab at the Cε3 epitope, we performed compe-
tition experiments using omalizumab. Samples con-
taining 600 ngml of IgE were incubated with the in-
dicated concentrations of omalizumab; thereafter,
free IgE levels in the samples were measured using
New Assay for Free IgE on Omalizumab Therapy
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Fig.　2　A. Assay scheme for determination of serum IgE levels in the presence of omalizumab. Recombinant 
high-affinity IgE receptor FcεRIα with the human form of sugar chain (rshFcεRIα) was used as the capture anti-
gen. B. Representative standard curve using human IgE. X-axis showing standard IgE concentrations ranging 
from 4.69 ng/ml to 600 ng/ml. Y-axis showing optical density (OD) values at 450 nm. Four-P Fit: y = (A - D)/(1 + 
(×/C)B) + D (A: 0.0148; B: 0.999; C: 930; D: 0.9993; R2: 1). C. The specifi city of detecting free IgE levels with 
ELISA using rshFcεRIα. Omitting rshFcεRIα or the detection antibody resulted in a loss of free IgE-derived sig-
nals over the entire concentration range (0-320 ng/ml).
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ELISA. As shown in Figure 4, adding omalizumab re-
duced free IgE levels in a dose-dependent manner.
Subsequently, we monitored weekly free IgE levels
in the serum of four asthmatic patients after the first
administration of omalizumab. Free IgE levels in all
these patients were significantly reduced after admin-
istering omalizumab (Fig. 5). It has been reported
that to maintain the benefit of omalizumab treatment
Ito R et al.
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Table　1　Accuracy of ELISA for measurement of the pooled sample
IgE Concentration (ng/ml)
0  4.69  9.38 18.75  37.5 75 150 300 600
Calculated conc.
(ng/ml) 15.23 19.92 29.29  48.04 85.54 160.54 310.54 610.54
Experimentally-found
conc. mean(ng/ml) 10.54 14.53 18.92 28.25  48.10 84.59 154.96 289.80 569.41
SD  1.93  3.25  2.47   2.36  5.59   7.69  10.94  19.09
Accuracy (%) 95.40 94.97 96.44 100.11 98.88  96.52  93.32  93.26
%CV 13.3 17.2  8.8   4.9  6.6   5.0   3.8   3.4
Detected spike
conc.-mean conc. In
serum (ng/ml)
Mean  3.37  7.76 17.09  36.94 73.43 143.80 278.64 558.25
Recovery (%) 71.92 82.74 91.15  98.50 97.91  95.87  92.88  93.04
Spike-recovery assays were used to determine the accuracy and precision of ELISA. Pooled serum from healthy controls was spiked us-
ing 4.69 ng/ml to 600 ng/ml of IgE. IgE concentration of the pooled serum was 10.54 ng/ml. Calculated concentration was 10.54 + spiked 
concentration of IgE. Accuracy is the difference between experimentally determined and calculated concentrations. Recovery (%) is the dif-
ference between detected spike and spiked IgE concentrations.
Fig.　3　A. Optimal dilution factor for serum samples. Serum samples obtained from healthy controls (No. 
1-6) were diluted by the factors from ×1 to ×32. IgE concentrations were then measured with ELISA using 
rshFcεRIα. B. Determination of the optimal dilution factor for serum samples. Serum samples obtained from 
healthy controls (No. 7-13) were diluted by the factors from ×10 to ×20. Subsequently, IgE levels were mea-
sured with ELISA using rshFcεRIα.
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in severe asthmatic patients, serum free IgE concen-
trations need to remain at <50 ngml.24 Thus, we ana-
lyzed trough free IgE levels in 54 asthmatic patients
undergoing omalizumab therapy. As shown in Figure
6, in 14 of 54 (25.9%) patients, the trough free IgE
concentration was >50 ngml. 11 of 54 (20.4%) pa-
tients was > 100 ngml and 6 of 54 (11.1%) patients
was >150 ngml. The frequency of appearance of the
omalizumab treated patients with over 50 ngml free
IgE appeared to be independent to the duration of
omalizumab therapy.
DISCUSSION
In this study, we developed an original ELISA-based
IgE measurement system using immobilized
rshFcεRIα with human sugar chains. To explore the
feasibility of using this method in clinical settings, we
optimized several assay conditions and validated the
measurement accuracy. We first studied the effect of
serum on the assay’s linearity over a range of serum
dilutions to determine the optimal serum dilution fac-
tor for this assay system. These results indicate that
the OD values decreased below a serum dilution fac-
tor of ×15 in a concentration-dependent manner. This
may be attributed to serum factors that inhibit IgE-
FcεRI binding (e.g., autoantibodies to IgE, soluble
low-affinity IgE receptors, lipoproteins, or sugar
chains). We accordingly selected ×15 as the serum di-
lution factor for this assay to eliminate interference
from inhibitory factors in serum and to enhance the
New Assay for Free IgE on Omalizumab Therapy
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Table　2　Accuracy of  ELISA for IgE measurements in sera from healthy controls and asthmatic patients
IgE (ng/ml)
Unspiked Spiked (75 ng/ml)
Sample Average SD CV (%) Average SD CV (%) Recovery (%)
Asthma 1 48.93 1.67  3.41 143.29  7.81 5345 125.8
2 26.9 1.51  5.61 114.87  6.11    5.32 117.3
3 35.72 2.84  7.94 106.83 13.75   12.87  94.81
4  2.8 0.75 26.73  83.61  6.57    7.86 107.75
5 64.79 5.45  8.41 145.62 11.77    8.08 107.78
6  3.39 0.61 17.99  89.27  8.25    9.25 114.49
7 17.38 1.55  8.93 107.06  4.64    4.33 119.57
Average    7.59 112.5
SD    2.71   9.35
Healty control 1 58.4 5.13  8.78 143.26  9.94    6.94 113.15
2  2.63 0.41 15.64  86.84  8.82   10.16 112.28
3  6.9 0.26  3.7  89.86  6.5    7.23 110.62
4 35.82 1.28  3.59 110.55 14.42   13.05  99.64
5  6.61 0.91 13.82  87.72 11   12.54 108.15
6 22.49 0.62  2.78  94.98 14.21   14.96  96.65
7  3.76 0.08  2.14  76.04 11.21   14.75  96.37
Average   11.38 105.27
SD    3.33   7.45
Spike-recovery assays were used to determine the accuracy and precision of ELISA regarding the measurement of the levels in sera from 
seven healthy controls and seven asthmatic patients. Pooled serum from healthy controls was spiked to 75 ng/ml of IgE. Recovery (%) is
the difference between detected spike and spiked IgE concentrations.
Table　3　Inter-assay variability of free IgE ELISA
IgE (ng/ml) Meann = 5 SD CV (%) Recovery (%)
600 564.06 20.23 3.56 92.15
300 285.4 8.83 3.09 91.41
150 153.55 8.92 5.81 94.93
75 84.11 6.68 7.94 97.26
37.5 48.58 2.7 5.56 99.78
18.75 28.85 2.7 9.37 94.34
9.38 19.67 3.65 18.56 90.74
4.69 14.83 2.27 15.28 78.4
Inter-assay variability for pooled samples containing from 4.69 
ng/ml to 600 ng/ml of IgE, as assessed on four different plates by 
two independent operators. Recovery (%) is the difference be-
tween detected spike and spiked IgE concentrations.
Table　4　Intra-assay variability of free IgE ELISA
IgE (ng/ml) Meann = 4 SD CV (%) Recovery (%)
600 575.14 14.52  2.53  95.86
300 289.27 14.11  4.88  96.42
150 152.66  8.29  5.43 101.77
75  74.72  2.49  3.33  99.63
37.5  36.96  2.25  6.07  98.56
18.75  16.22  1.31  8.05  86.53
9.38  7.2  0.69  9.64  76.84
4.69   3.06  0.51 16.49  65.36
Intra-assay variability for pooled samples containing from 4.69 
ng/ml to 600 ng/ml of IgE, as assessed on nine replicates of indi-
vidual samples on a single plate. Recovery (%) is the difference 
between detected spike and spiked IgE concentrations.
assay’s sensitivity.
Conforming to the acceptance criteria for immuno-
validation, the acceptable assay range was defined
based on the result from the spike-recovery assay as
the concentration range that satisfied the CV% of
20% and the recovery rate of 80%-120%. Conse-
quently, LLOQ and ULOQ were determined to be
9.38 ngml and 600 ngml, respectively. These are
corresponding to 140.7 ngml and 9000 ngml of se-
rum IgE of concentration respectively. Although the
LLOQ value was higher compared with that of previ-
ously reported assay methods, our method appears to
be sufficiently sensitive to determine the level of free
IgE remaining in the serum.
In the error assessments where samples from asth-
matic patients and healthy controls were tested indi-
vidually, CV% ranged from 4.33% to 14.96%, with a
mean of 7.59% ± 2.71% for asthmatic patients and a
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Fig.　4　Reduced serum free IgE levels due to the addition 
of omalizumab. Pooled serum containing 600 ng/ml of IgE 
was incubated with the indicated amounts of omalizumab; 
thereafter, free IgE levels were measured. Data are repre-
sentative of two independent experiments with similar re-
sults.
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mean of 11.38% ± 3.33% for healthy controls. This indi-
cated good accuracy in general, although the recov-
ery rate exceeded 120% in one case. The observed dif-
ference in assay variability among individual cases
may reflect differences in the amounts of serum fac-
tors that may inhibit IgE-FcεRIα binding. Neverthe-
less, the error range was deemed acceptable because
no extreme outliers were observed.
Based on these results, this assay method permit-
ted measurement of serum IgE in clinical samples
with sufficient accuracy. We measured free IgE levels
in sera from asthmatic patients undergoing omalizu-
mab therapy using the aforementioned assay system.
To test this method for its applicability to free IgE as-
says in the presence of omalizumab, we first exam-
ined whether omalizumab added to the sample in vi-
tro reduced the serum free IgE level in a dose-
dependent manner. As shown in Figure 4, adding
omalizumab reduced free IgE levels in samples in a
concentration-dependent manner.
Subsequently, changes in free IgE levels were
monitored over time following implementation of the
initial therapy. In each of the four cases assessed, se-
rum free IgE levels decreased immediately after the
omalizumab administration (Fig. 5). This result was
in accord with that of previous clinical trials on pa-
tients with bronchial asthma and allergic rhinitis, in
which a rapid decline in serum free IgE levels was
documented after the initiation of omalizumab ther-
apy. However, trough free IgE levels were elevated
and, in particular, exceeded 50 ngml after the sec-
ond administration in certain cases for which the ad-
ministration interval was 4 weeks (Cases 3 and 4).
For these cases, omalizumab dose selection based on
body weight and pretreatment serum IgE levels may
have been insufficient to reduce the serum free IgE
level to the targeted level.
The aforementioned study2,18,25,26 also revealed
that free IgE concentrations did not decline to the tar-
get value24 of 50 ngml in some cases undergoing
short-term therapy after the administration of omali-
zumab. This led us to suspect that among severe
asthmatic patients on long-term omalizumab therapy,
some cases may exist for which serum free IgE levels
fail to reach the target level. Thus, we measured
trough free IgE levels after omalizumab administra-
tion in 54 cases that were on omalizumab for more
than 4 weeks (Fig. 6). These results indicate that 40
of 54 (74.1%) cases had free IgE levels that reached
the therapeutic target for omalizumab treatment (i.e.,
50 ngml). This underruns previously reported out-
come 99.2%.27 A possible reason is that the rshFcεRIα
construct used in our assays is different from the re-
combinant proteins used in other studies, which may
have resulted in differences in IgE measurements.
Recombinant rshFcεRIα protein constructs used in
most previous studies were mostly expressed in E.
coli or a baculovirus vectorinsect cell expression
system28,29 in which the amino acid sequences of the
expressed proteins were identical to those of the hu-
man protein; however, the sugar chain structures
could have been different from those of the human
protein. These structural differences in sugar chains
may affect the binding affinity of IgE and its FcεRIα
receptor. This difference in binding affinity possibly
alters the equilibrium state among IgE, IgE-
omalizumab complexes, and IgE-FcεRIα binding in
an assay system. As a consequence, measurement
systems that use immobilized FcεRIα preparations
with different sugar chain structures may give differ-
ent IgE readings in the presence of omalizumab. We
did not address which system could measure free IgE
levels more accurately in the presence of omalizu-
mab.
Nevertheless, it is conceivable that our system bet-
ter approximates the physiological equilibrium that
occurs in the human body compared with other assay
methods, because our method uses an FcεRIα con-
struct comprising the human form of the sugar chain.
Considering that the objective of these measure-
ments is to quantify the IgE subfraction that can bind
to FcεRIα in the human body in the presence of
omalizumab, it is reasonable that our assay system
can detect the effect of omalizumab more accurately.
Although our results suggest that our assay system is
effective for predicting the responsiveness of certain
patients to omalizumab therapy, we could not analyze
the relationships between free IgE levels measured
by this method and clinical data in the present study.
Previously, several methods for measuring free IgE
under the presence of omalizumab has been re-
ported,26 including the recovery-ELISA system.30 The
New Assay for Free IgE on Omalizumab Therapy
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Fig.　5　Measurement of IgE levels in patient sera. Serum free IgE levels (fi lled squares) in 
four asthmatic patients after the fi rst administration of omalizumab were determined using 
ELISA. Total IgE levels (fi lled circles) were measured by ImmunoCap IgE. Arrows show the 
time points for omalizumab administration.
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Fig.　6　Free IgE levels in 54 asthmatic patients undergoing 
omalizumab therapy. Trough free IgE levels in sera from 54 
different patients treated with omalizumab for one month to 
51 months were measured by ELISA. Dashed line indicates 
50 ng/ml of free IgE.
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free IgE concentration in a serum specimen from pa-
tients administered with omalizumab was measured
by the recovery-ELISA system based on (1) creating
a calibration curves of various concentration of stan-
dard IgE under various concentrations of omalizu-
mab solutions; (2) creating a correlation formula of
the relationship between IgE and omalizumab from
the calibration curves; (3) spiking the standard IgE
into clinical specimens of patients administered with
omalizumab and based on the degree of absorbency
obtained; (4) calculating the concentrations of both
free IgE and free omalizumab using the formula. In
the present study, the ratio of the patients who
reached the therapeutic target for omalizumab treat-
ment was lower than previously reported outcomes
ranging from 73% to 99.2%, based on the values meas-
ured by other assays including the recovery-ELISA
system. One possible reason of this difference is that
the rshFcεRIα construct used in our assays is differ-
ent from the recombinant proteins used in other stud-
ies, which may have resulted in differences in IgE
measurements. In addition, although our assay is
based on simple ELISA method, the method of
recovery-ELISA system is fundamentally different
from a simple ELISA. With This method has an ad-
Ito R et al.
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vantage on sensitivity, because undiluted serum is
used as a specimen. However, it is difficult to evaluate
the accuracy of the recovery-ELISA system, because
the recovery rate cannot be directly measured. Fur-
thermore, there are no detailed reports on variability
of this method has not been reported. Therefore, we
cannot evaluate which assay is closer to the true
value. Further analysis with a larger number of pa-
tients should be conducted in future studies.
In summary, we developed a new ELISA-based as-
say system to determine serum free IgE levels using
immobilized soluble human FcεRIα that were gener-
ated by gene recombination. Using this assay system,
we measured free IgE levels in sera from asthmatic
patients undergoing omalizumab therapy. This
method permitted monitoring of serum free IgE lev-
els. It is expected to realize assessments of appropri-
ate omalizumab doses for nonresponders. In addition,
even for responders, it provides for optimization of
doses and dosing intervals. Optimized dosing regi-
mens will aid in resolving medical expense issues and
benefit a wider range of patients. Although a direct
comparison was not performed, our method may be
superior to conventional free IgE assay methods
based on FcεRIα with nonhuman form of sugar
chains in terms of binding affinity to human serum
IgE.
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